tranexamic acid has been researched along with Orphan Diseases in 2 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Orphan Diseases: Rare diseases that have not been well studied.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Tranexamic acid (TA) has been widely used in the treatment of these severe bleeds but with no properly designed trial." | 6.79 | Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease. ( Boutitie, F; Capitaine, AL; Dupuis-Girod, S; Gaillard, S; Gueyffier, F; Hatron, PY; Kaminsky, P; Manfredi, G; Morinière, S; Plauchu, H; Rivière, S; Roy, P, 2014) |
| "Tranexamic acid (TA) has been widely used in the treatment of these severe bleeds but with no properly designed trial." | 2.79 | Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease. ( Boutitie, F; Capitaine, AL; Dupuis-Girod, S; Gaillard, S; Gueyffier, F; Hatron, PY; Kaminsky, P; Manfredi, G; Morinière, S; Plauchu, H; Rivière, S; Roy, P, 2014) |
| "Glanzmann thrombasthenia (GT) is a rare bleeding syndrome, which is characterized by a lack of platelet aggregation." | 1.36 | Glanzmann thrombasthenia detected because of knee hemarthrosis: a case report. ( Ishiguro, N; Katsumi, A; Nishida, Y; Tsukushi, S; Urakawa, H, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gaillard, S | 1 |
| Dupuis-Girod, S | 1 |
| Boutitie, F | 1 |
| Rivière, S | 1 |
| Morinière, S | 1 |
| Hatron, PY | 1 |
| Manfredi, G | 1 |
| Kaminsky, P | 1 |
| Capitaine, AL | 1 |
| Roy, P | 1 |
| Gueyffier, F | 1 |
| Plauchu, H | 1 |
| Urakawa, H | 1 |
| Nishida, Y | 1 |
| Tsukushi, S | 1 |
| Katsumi, A | 1 |
| Ishiguro, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Tranexamic Acid to Prevent OpeRation in Chronic Subdural Hematoma. A Double-blind, Placebo-controlled, Multicentre, Randomized Controlled Clinical Trial[NCT03582293] | Phase 3 | 140 participants (Anticipated) | Interventional | 2018-06-19 | Recruiting | ||
| ATERO : A Randomised Study With Tranexamic Acid in Epistaxis of Rendu Osler Syndrome. Beneficial or Iatrogenic Effects.[NCT00355108] | Phase 3 | 170 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for tranexamic acid and Orphan Diseases
| Article | Year |
|---|---|
Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease.
Topics: Adult; Aged; Antifibrinolytic Agents; Cross-Over Studies; Double-Blind Method; Epistaxis; Europe; Fe | 2014 |
Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease.
Topics: Adult; Aged; Antifibrinolytic Agents; Cross-Over Studies; Double-Blind Method; Epistaxis; Europe; Fe | 2014 |
Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease.
Topics: Adult; Aged; Antifibrinolytic Agents; Cross-Over Studies; Double-Blind Method; Epistaxis; Europe; Fe | 2014 |
Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease.
Topics: Adult; Aged; Antifibrinolytic Agents; Cross-Over Studies; Double-Blind Method; Epistaxis; Europe; Fe | 2014 |
1 other study available for tranexamic acid and Orphan Diseases
| Article | Year |
|---|---|
Glanzmann thrombasthenia detected because of knee hemarthrosis: a case report.
Topics: Antifibrinolytic Agents; Arthralgia; Bleeding Time; Child; Diagnosis, Differential; Hemarthrosis; Hu | 2010 |